Lyssikatos Joseph P 4
Research Summary
AI-generated summary
Enliven (ELVN) CSO Joseph P. Lyssikatos Sells 5,000 Shares
What Happened
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares in an open‑market transaction on February 6, 2026. The weighted average sale price was $29.04 per share, for total proceeds of $145,219. This was a sale (not a purchase or option exercise).
Key Details
- Transaction date: February 6, 2026 (reported on Form 4 filed February 10, 2026). No late filing is indicated in the document.
- Transaction type/code: Sale (S), executed as multiple trades; prices ranged from $28.925 to $29.14 (weighted average $29.04).
- Shares sold: 5,000; Proceeds: $145,219.
- Shares owned after transaction: Not disclosed on this Form 4.
- Footnotes of note:
- F1: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted November 15, 2024.
- F2: Multiple trades at varying prices; reporting person will provide breakdown of individual trade prices upon SEC/issuer/stockholder request.
- F3: The shares sold were held by The Lyssikatos Revocable Trust (12/15/2011), for which Lyssikatos serves as trustee.
Context
Sales under prearranged 10b5‑1 plans are common and typically pre-scheduled, so they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases usually carry more informational weight than routine, preplanned sales.